Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort

Archive ouverte

Pouletty, Marie | Borocco, Charlotte | Ouldali, Naïm | Caseris, Marion | Basmaci, Romain | Lachaume, Noémie | Bensaid, Philippe | Pichard, Samia | Kouider, Hanane | Morelle, Guillaume | Craiu, Irina | Pondarre, Corinne | Deho, Anna | Maroni, Arielle | Oualha, Mehdi | Amoura, Zahir | Haroche, Julien | Chommeloux, Juliette | Bajolle, Fanny | Beyler, Constance | Bonacorsi, Stéphane Pierre Paul | Carcelain, Guislaine | Koné-Paut, Isabelle | Bader-Meunier, Brigitte | Faye, Albert | Meinzer, Ulrich | Galeotti, Caroline | Melki, Isabelle

Edité par CCSD ; BMJ Publishing Group -

International audience. Background Current data suggest that COVID-19 is less frequent in children, with a milder course. However, over the past weeks, an increase in the number of children presenting to hospitals in the greater Paris region with a phenotype resembling Kawasaki disease (KD) has led to an alert by the French national health authorities. Methods Multicentre compilation of patients with KD in Paris region since April 2020, associated with the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ( € Kawa-COVID-19'). A historical cohort of € classical' KD served as a comparator. Results Sixteen patients were included (sex ratio=1, median age 10 years IQR (4·7 to 12.5)). SARS-CoV-2 was detected in 12 cases (69%), while a further three cases had documented recent contact with a quantitative PCR-positive individual (19%). Cardiac involvement included myocarditis in 44% (n=7). Factors prognostic for the development of severe disease (ie, requiring intensive care, n=7) were age over 5 years and ferritinaemia >1400 μg/L. Only five patients (31%) were successfully treated with a single intravenous immunoglobulin (IVIg) infusion, while 10 patients (62%) required a second line of treatment. The Kawa-COVID-19 cohort differed from a comparator group of € classical' KD by older age at onset 10 vs 2 years (p<0.0001), lower platelet count (188 vs 383 G/L (p<0.0001)), a higher rate of myocarditis 7/16 vs 3/220 (p=0.0001) and resistance to first IVIg treatment 10/16 vs 45/220 (p=0.004). Conclusion Kawa-COVID-19 likely represents a new systemic inflammatory syndrome temporally associated with SARS-CoV-2 infection in children. Further prospective international studies are necessary to confirm these findings and better understand the pathophysiology of Kawa-COVID-19. Trial registration number NCT02377245

Consulter en ligne

Suggestions

Du même auteur

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Archive ouverte | Matuozzo, Daniela | CCSD

International audience

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Archive ouverte | Matuozzo, Daniela | CCSD

International audience. Background - We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IF...

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

Archive ouverte | Manry, Jérémy | CCSD

International audience. Significance There is growing evidence that preexisting autoantibodies neutralizing type I interferons (IFNs) are strong determinants of life-threatening COVID-19 pneumonia. It is important t...

Chargement des enrichissements...